Context: Upregulated brain glucose transport in response to recurrent hypoglycemia may contribute to the development of hypoglycemia-associated autonomic failure (HAAF) and impaired awareness of hypoglycemia. Whether recurrent hypoglycemia alters glucose transport in the hypothalamus is unknown.
I
nsulin-induced hypoglycemia is a common event in the lives of patients with diabetes. In a recent international study, 83% of all enrolled patients with type 1 diabetes had at least one episode of hypoglycemia each month (1) . When these events occur in close proximity to each other, hypoglycemia-associated autonomic failure (HAAF) and impaired awareness of hypoglycemia may ensue; consequently, the first symptom of low blood glucose will be confusion or unconsciousness. In health, humans have a robust and redundant counterregulatory response that prevents the development of hypoglycemia, but in type 1 diabetes, this response is impaired on many levels (2) . When blood glucose falls to 80 to 90 mg/dL, patients with type 1 diabetes are unable to normally reduce endogenous insulin secretion because of the b-cell failure associated with their disease. As glucose continues to fall, they are also unable to release glucagon in response to hypoglycemia, likely because of a failure to reduce levels of insulin within the islet in response to the falling glucose (3) . Such patients come to rely on hypoglycemia-induced secretion of epinephrine from the adrenal medulla and norepinephrine from the sympathetic nerves to cause the adrenergic symptoms typically associated with low blood sugar to signal the need to ingest carbohydrates. When hypoglycemia occurs frequently in a short period, HAAF and impaired awareness of hypoglycemia develops, and the blood glucose level that triggers catecholamine release is reduced into the range at which humans experience neuroglycopenia.
The mechanisms responsible for the development of HAAF and impaired awareness of hypoglycemia remain uncertain (4, 5) . Clearly, increased fuel availability to the brain, in the form of either glucose or alternative fuels, can result in a failure to detect systemic hypoglycemia, the "unawareness" component of HAAF. Although there are conflicting data on whether global cerebral glucose transport or metabolism are altered in HAAF (6) (7) (8) , regional alterations seem likely, particularly in the hypothalamus, the region that senses systemic glucose and coordinates the counterregulatory response (9) (10) (11) . We have previously demonstrated that steady-state glucose concentrations in the occipital cortex are significantly higher in subjects with type 1 diabetes and impaired awareness of hypoglycemia than in age-, sex-, and body mass index-matched controls studied under the same conditions (12) . We have interpreted these data to suggest that brain glucose transport is upregulated in response to recurrent hypoglycemia and have proposed that this is one mechanism that contributes to the development of HAAF. However, research to date does not provide evidence of how recurrent hypoglycemia alters glucose transport or metabolism in the hypothalamus.
In this study, we used recently developed magnetic resonance imaging methodology that permits measurement of hypothalamic glucose concentration changes in humans (13) to determine how recurrent hypoglycemia alters glucose transport in this region. In these experiments, we measured glucose transport after inducing HAAF in healthy humans using a well-established preconditioning protocol; specifically, we measured the ratio of maximal transport rate to cerebral metabolic rate of glucose (T max /CMR glc ) in the hypothalamus of healthy volunteers with and without induction of HAAF. We hypothesized that recurrent hypoglycemia, like that seen in subjects with type 1 diabetes and iatrogenic hypoglycemia, will lead to an increase in glucose uptake in the hypothalamus, thereby facilitating maintenance of cerebral metabolism during subsequent episodes of hypoglycemia.
Materials and Methods

Subjects
Thirteen healthy subjects [age 31 6 11 years; four females and nine males; BMI 27 6 8 kg/m 2 (mean 6 SD)] were enrolled after giving informed consent using procedures approved by the University of Minnesota Institutional Review Board: Human Subjects Committee. All procedures performed were in accordance with the 1975 Declaration of Helsinki and its later amendments. Exclusion criteria included history of ischemic heart disease, arrhythmia, seizure disorder, or being on medications known to alter blood flow or carbohydrate metabolism, in addition to magnetic resonance safety criteria (claustrophobia, weight over 300 pounds, and presence of paramagnetic metal in the body). Subjects underwent paired hypoglycemic and euglycemic preconditioning studies, except for one subject who only underwent euglycemic preconditioning and another who only underwent hypoglycemic preconditioning, resulting in 12 datasets with euglycemic preconditioning and 12 with hypoglycemic preconditioning. Subjects were asked to avoid strenuous exercise for 24 hours before the start of each preconditioning protocol.
Experimental design
To induce HAAF in healthy volunteers, subjects underwent hypoglycemic preconditioning: two hypoglycemic clamps, in the morning and afternoon on day 1, and a third hypoglycemic clamp in the morning on day 2 (Fig. 1) . Control experiments with euglycemic preconditioning included three 2-hour euglycemic clamps at the same times over 2 days. Euglycemic and hypoglycemic preconditioning experiments in the same subject were done in random order separated by at least 1 month. After preconditioning, hypothalamic glucose transport was measured by magnetic resonance spectroscopy (MRS) in the afternoon on day 2 of each preconditioning protocol (Fig. 1 ).
Euglycemic and hypoglycemic preconditioning protocol
Preconditioning studies included 2-hour clamps in the morning (8:00 to 10:00 AM) and afternoon (12:00 to 2:00 PM) of day 1 and a third clamp on the morning (8:00 to 10:00 AM) of day 2, as described previously (14) . Briefly, subjects arrived at the Clinical and Translational Science Institute in the morning after an overnight fast. For the clamps, insulin was administered intravenously (IV) at a rate of 2.0 mU/kg/min and potassium phosphate administered at a rate of 4 mEq/h. Arterialized blood samples (15) were collected every 5 minutes for the measurement of plasma glucose. For hypoglycemic clamps, plasma glucose was allowed to fall to 50 mg/dL and then maintained at this level by a variable infusion of 20% dextrose. For euglycemic clamps, plasma glucose was maintained at ;90 mg/dL. Approximately 2 hours after starting insulin, the insulin and potassium were discontinued, and the blood glucose was normalized with 20% dextrose infusion. Samples for glucagon, epinephrine, norepinephrine, and cortisol were drawn at baseline (30 minutes after the placement of the last IV catheter) and at 60, 90, and 120 minutes after starting insulin during the first and third clamps. We concluded that HAAF was induced successfully if hypoglycemiainduced epinephrine secretion was at least 20% lower during the third hypoglycemic clamp compared with the first, a magnitude of blunting similar to that seen in other studies (16, 17) .
After the first and third clamps, hypoglycemia symptoms were quantified by using a previously validated questionnaire (18) . Subjects were asked to score from 0 (none) to 6 (severe) each of 12 symptoms: 6 autonomic symptoms (heart pounding, shaky/tremulous, nervous/anxious, sweaty, hungry, and tingling) and 6 neuroglycopenic symptoms (difficulty thinking, tired/drowsy, weak, warm, faint, and dizzy).
MRS study protocol
Subjects were prepared for the MRS study, on the afternoon of each day 2, by the placement of an antegrade IV infusion catheter into one arm for infusion and the placement of a retrograde IV infusion catheter into one leg for subsequent blood sampling. The leg used for sampling was wrapped in heated towels and hot packs to arterialize the venous blood (15) .
MR data were acquired at 3T on a Siemens Trio scanner (software version, Syngo VB17A; Siemens Medical, Erlangen, Germany) using a body coil transmit and a 32-channel phasedarray receive coil, as previously described (13) . MRS calibrations were performed, and baseline MRS data were collected during euglycemia (90 to 100 mg/dL blood glucose) (Fig. 1 ). Subjects were then given an IV bolus injection of 20% dextrose, followed by a continuous infusion to maintain the desired blood glucose ([Glc]) target in the 200-to 400-mg/dL range for ;60 minutes, as described previously (13) . One of three target hyperglycemic levels [200 mg/dL (11 mM), 300 mg/dL (16.5 mM), and 400 mg/dL (22 mM)] was selected for each subject according to a randomization table to obtain steady-state brain vs plasma glucose concentrations over a wide range of plasma glucose concentrations and to sufficiently populate the brain vs plasma glucose curve for modeling of glucose transport (19) . Specifically, four subjects were assigned to the 200-mg/dL target, five to the 300-mg/dL target, and three to the 400-mg/dL target in each of the euglycemic and hypoglycemic preconditioning groups. MRS data were collected continuously for the duration of the study, and blood glucose was measured in samples collected every 2 to 5 minutes (Fig. 1) . Figure 1 . Experimental protocol. In random order, subjects underwent hypoglycemia or euglycemia preconditioning with two clamps on day 1 and a third clamp on day 2. In each clamp study, insulin was administered IV at a rate of 2.0 mU/kg/min. Glucose target was 50 mg/dL during hypoglycemia precondition and 90 mg/dL during euglycemia precondition. The MRS study during hyperglycemia was done in the afternoon of day 2 in each precondition protocol. During the MR scan, a baseline spectrum was acquired at euglycemia, followed by an IV bolus, variable rate 20% dextrose infusion, and continuous MRS acquisitions from the hypothalamus for ;1 hour. Each MR spectrum was acquired over 10.6 minutes. Times indicated are approximate. (20) , proton spectra were acquired from the hypothalamus (10 3 12 3 13 mm 3 ) using a modified semi-LASER sequence (TR/TE 5000/28 ms; 128 transients per data point) (21) . Cerebrospinal fluid content of the VOI was determined based on registration of low-resolution 35-second FLASH images, which were interleaved between metabolite acquisitions, to the high-resolution MPRAGE image acquired at the beginning of the scanning session, as described previously (13) . The scanning session was completed within 90 minutes, during which a baseline spectrum was obtained during euglycemia, and up to six spectra were obtained during hyperglycemia (Fig. 1) .
Metabolites were quantified using LCModel (22) with water-scaling (version 6.3-0G), a basis set consisting of 18 simulated metabolites (23, 24) and a previously measured macromolecular basis set (25) . The sum of glucose and taurine, [Glc+Tau] , is reported rather than glucose alone in accordance with LCModel guidelines by which metabolites with strong negative cross correlations (,20.5) be reported also as a sum of the two metabolites (26) . Although we show the sum of these two metabolites in our results, the observed changes in [Glc+Tau] over the glucose infusion time course are attributed to changes in [Glc] based on results obtained by LCModel fitting of summed spectra obtained from subjects with plasma glucose targets $300 mg/dL. The resulting LCModel quantification showed changes in [Glc], but not in [Tau] , between the summed baseline and the summed later time point spectra (13) . The reliable data points in each [Glc+Tau] time course were selected based on criteria identified in our prior study (13) , namely water linewidths #10 Hz, head motion ,3 mm in any direction, and Cramér-Rao lower bounds #50%. No data points were discarded based on the Cramér-Rao lower bound threshold.
Laboratory analyses
Plasma glucose concentration was measured in duplicate during the clamps and MR scanning using an Analox machine (Analox Instruments, Stourbridge, UK). Serum insulin concentrations were obtained by a chemiluminescent assay (Immulite; Diagnostic Products Corporation, Los Angeles, CA). Counterregulatory hormones were assayed at the Vanderbilt Diabetes Research and Training Center core laboratory. Plasma epinephrine and norepinephrine were measured by high-performance liquid chromatography (Dionex Corp, Sunnyvale, CA). Radioimmunoassay was used to measure plasma cortisol (Diagnostic Products Corporation) and glucagon (Merck Millipore, Billerica, MA).
Modeling of hypothalamic glucose transport
Steady-state brain glucose concentrations were measured when blood glucose had been stable for $20 minutes. Steadystate data points fitting this criterion were selected by visual inspection of the time courses of plasma and brain glucose concentration. This selection was performed independently by three investigators (A.M., J.M.J., and G.Ö.) and gave nearly identical results. Measures of hypothalamic glucose were based on spectra collected over a 10. 
Statistical analysis
Summary statistics and paired, two-tailed t tests were used to compare mean plasma glucose and counterregulatory hormone levels and symptom scores between the first and third clamps of each preconditioning protocol. Data are presented as mean 6 standard error of the mean (SEM) unless otherwise stated, and threshold for statistical significance was set to P , 0.05.
Because the T max /CMR glc fit yielded a single value for each group, the error (SEM) for each group was determined by Monte-Carlo simulation (repeating the fit 1000 times with different noise realizations HYPO,i ; N = 5) were used for a pairedsample t test. In the second analysis, those with complete pairs (N = 5) and those with a [Glc+Tau] available for either [Glc*] EU,i or [Glc*] HYPO,i , but not both (N = 7), were used. A linear mixed model with a random intercept for participant (to account for the pairing) was fit in which the intercept variance was allowed to differ by preconditioning protocol because the [Glc+Tau] variability in the hypoglycemic preconditioning protocol was substantially larger than in the euglycemic preconditioning protocol. In this model, the test of interest (on the factor for euglycemic vs hypoglycemic preconditioning protocol) was adjusted for [Glc*], the plasma glucose value concurrent with the [Glc+Tau] determination.
Results
During the euglycemic preconditioning clamps, blood glucose was maintained at the euglycemic target, and during the hypoglycemic preconditioning clamps, the hypoglycemic targets were successfully achieved and maintained with no differences among clamps 1, 2, and 3 (Fig. 2) . HAAF was successfully induced in 7 out of 11 subjects who completed both preconditioning protocols and in the 1 subject who completed only the hypoglycemic preconditioning protocol, based on blunted counterregulatory hormone responses. Namely, the counterregulatory hormone response measured during euglycemic clamp 3 was essentially the same as during euglycemic clamp 1, whereas the counterregulatory hormone response measured during hypoglycemic clamp 3 was lower than that measured during hypoglycemic clamp 1 in those subjects with successful HAAF induction. Statistically substantial reductions were noted in epinephrine, glucagon, and cortisol secretions, but no changes were found in norepinephrine secretion (Table 1) . Symptom scores tended to be lower at hypoglycemic clamp 3 vs clamp 1.
Good-quality MR spectra were successfully acquired despite the small size and deep location of the VOI in the hypothalamus (Fig. 3) . Hyperglycemic plasma glucose targets were successfully achieved within ;5 to 20 minutes of the bolus during the MR study (Fig. 4) and maintained for the remainder of the scanning session for each subject. As expected, hypothalamic glucose concentrations, more specifically [Glc+Tau], consistently increased as blood glucose concentrations were experimentally increased (Fig. 4) .
Data from the subjects with euglycemic preconditioning (N = 12) and the subjects with successful HAAF induction after hypoglycemic preconditioning (N = 8) were used to determine if hypothalamic glucose transport changed following recurrent hypoglycemia. Specifically, the slope of the hypothalamic [Glc+Tau] vs plasma [Glc] curve was compared between the euglycemic and hypoglycemic preconditioning studies (Fig. 5) . Using the reversible Michaelis-Menten model, T max /CMR glc was 1.62 6 0.1 following euglycemia preconditioning and 1.75 6 0.14 after hypoglycemia preconditioning (P was not significant) (Fig. 5) . Because detecting a change in hypothalamic [Glc+Tau] at the low hyperglycemic target (200 mg/dL) vs baseline measurements is less reliable than for higher targets (13), we also fit our regressions allowing for each target group to have a different variance estimate. Variances were different by target, as expected; however, the point estimates for the slope of brain [Glc+Tau] on glucose did not change appreciably. Finally, using the paired [Glc+Tau] data, neither analysis (paired t test nor linear mixed model) showed considerable differences between hypothalamic glucose concentrations measured during hyperglycemia for the two preconditioning protocols.
Discussion
In this experiment, we measured hypothalamic glucose concentrations in healthy humans after undergoing a preconditioning protocol to experimentally induce HAAF with the goal of testing the hypothesis that increased glucose transport into the hypothalamus contributes to the development of impaired awareness of hypoglycemia. Despite the successful induction of HAAF in most of our volunteers and the use of highly sophisticated methodology to measure glucose concentration changes in this small and central region of the brain, we were unable to find differences in hypothalamic glucose transport kinetics calculated from data collected following each of the preconditioning protocols. Our findings do not support the hypothesis that recurrent hypoglycemia leads to an increase in hypothalamic glucose transport that ensures the glucose-sensing regions have sufficient fuel during systemic hypoglycemia to prevent a counterregulatory response.
Impaired awareness of hypoglycemia is a clinically important problem in insulin and secretagogue-treated patients with type 1 and type 2 diabetes. When such patients are exposed to recurrent hypoglycemia in a short period of time, the counterregulatory hormone and symptom responses to hypoglycemia are reduced and not elicited until after the development of neuroglycopenia. In these experiments, we chose to examine the effects of recurrent hypoglycemia sufficient to induce HAAF in 16 Data are shown for all euglycemic preconditioning studies (N = 12) and the successful hypoglycemic preconditioning studies (N = 8) by which HAAF was induced (mean 6 SEM between subjects). Plasma glucose data are averages from seven blood samples obtained from 90 to 120 minute in each individual. Hormone and symptom score data represent an average of 90-and 120-minute data. a Paired two-tailed t test. H-MRS of human hypothalamus. Good-quality MR spectra were acquired from the hypothalamic voxel (10 3 12 3 13 mm 3 ) as described in the text (semi-LASER, TE 28 ms, TR 5 seconds, and 128 transients). The voxel location is shown on the T1-weighted images. The spectrum was apodized with line broadening (1 Hz) and Gaussian multiplication (0.12 seconds) for display purposes. Glx, glutamate + glutamine; mI, myoinositol; NAA, N-acetylaspartate; PPM, parts per million; tCho, total choline; tCr, total creatine. healthy volunteers so we could distinguish between the effects of diabetes and recurrent hypoglycemia on the development of impaired awareness of hypoglycemia. In our previous work, we demonstrated that steadystate concentrations of glucose in the occipital lobes of patients with type 1 diabetes and impaired awareness of hypoglycemia were significantly higher than concentrations measured in healthy volunteers at the same blood glucose concentrations (12) . In contrast, we did not find a difference in occipital lobe glucose concentrations of healthy volunteers following three shorter (30-minute) episodes of hypoglycemia vs euglycemic control experiments (16), consistent with the current findings. Similarly, global rates of blood-to-brain glucose transport as measured by positron emission tomography (PET) were found the same in healthy subjects preconditioned with hypoglycemia to induce HAAF and those preconditioned with euglycemia (8) . Interestingly, no differences were found in global brain glucose transport parameters measured by PET between clinically aware and unaware men with type 1 diabetes (10) and in occipital lobe T max /CMR glc by MRS between patients with uncomplicated, reasonably well-controlled type 1 diabetes and awareness of hypoglycemia vs healthy controls (27) . Perhaps these findings suggest that the simultaneous presence of both diabetes and HAAF are necessary to determine if upregulation of glucose transport contributes to the impaired awareness seen in patients with diabetes. If so, future studies should consider subjecting participants with diabetes to preconditioning protocols that induce HAAF before measuring rates of glucose transport. Alternatively, it is also possible that the HAAF model, with its reduction in hypoglycemia-induced epinephrine, is not truly representative of the impaired awareness of hypoglycemia seen in patients with diabetes. The symptom scores measured during hypoglycemia were not statistically different following the two preconditioning protocols, which suggests that the awareness of hypoglycemia was not altered by our protocol despite the observed changes in the counterregulatory response.
Regarding changes in glucose metabolism upon recurrent hypoglycemia, we did not find a difference in the rates of glucose flux into the tricarboxylic acid cycle in the occipital lobes of patients with type 1 diabetes and impaired awareness of hypoglycemia vs healthy controls (28) . Other investigators have examined brain glucose metabolism in patients with type 1 diabetes and awareness of hypoglycemia and found them to have the same rates of brain glucose metabolism and glucose transport parameters as nondiabetic controls as measured by PET (29) and the same rates of glucose flux into the tricarboxylic acid cycle under euglycemic and hypoglycemic conditions (30) . Interestingly, when van de Ven et al. (30) compared the data collected from the type 1 subjects with data collected previously from healthy controls, they found the glucose flux was greater during hypoglycemia in the subjects with uncomplicated diabetes. They also found an inverse relationship between hemoglobin A1c and rates of glucose flux in their small group of subjects with type 1 diabetes and concluded that such patients are able to endure moderate hypoglycemia better than controls. It is uncertain if similar observations would be made in subjects with type 1 diabetes and impaired awareness of hypoglycemia, and future studies should include this subject group. It is possible that whatever adaptation made in response to recurrent hypoglycemia that leads to impaired awareness of hypoglycemia requires ongoing exposure to episodic hyperglycemia and diabetes, something that was not present in the current examination of healthy volunteers.
Metabolic insults like hypoglycemia are experienced by all parts of the brain simultaneously. However, it is unknown if different brain regions adapt differently to changes in fuel delivery or other stresses conveyed via the blood stream. The hypothalamus plays a central role in the regulation of many metabolic processes and is the primary region responsible for sensing changes in glycemia. Because of its small size and central location, studies of the human hypothalamus in vivo have been limited, and many investigators, including us, have extrapolated observations made in other brain regions to what occurs in the hypothalamus. In this report, we used a method that used a short-echo, full-intensity single-voxel localization method (21, 25) , retrospective assessment of dynamic voxel location during an MRS time series acquisition using interleaved FLASH images, dynamic cerebrospinal fluid correction, and predetermined quality acceptance criteria (13) to directly measure hypothalamic metabolites including glucose and used these data to calculate glucose transport kinetics. However, even with these technical advances, we were unable to obtain data from individual hypothalamic nuclei. Glucose-sensing neurons in the ventromedial nucleus of the hypothalamus are believed to respond to a fall in blood sugar and trigger the counterregulatory response necessary to restore euglycemia (9) . The volume occupied by these neurons in the human hypothalamus is unknown, but is no doubt smaller than the ;1.5 cm 3 voxel from which we collected spectroscopic data. Because the metabolites measured in our voxel reflect the mean of metabolite concentrations over the entire VOI, it is possible that we were unable to detect hypoglycemiainduced changes in glucose transport in the ventromedial nucleus of the hypothalamus because we did not have the sensitivity to isolate this signal from all of the other glucose molecules in the region. Interestingly, the T max / CMR glc values we estimated for the hypothalamus in this study (1.6 to 1.8) were somewhat lower than those we and others have reported for cortical T max /CMR glc (1.8 to 2.3) using similar MRS methodology and reversible Michaelis-Menten modeling (19, 31, 32) . The meaning of this observation is unclear because we are unable to determine if the lower T max /CMR glc is because of a lower T max or a higher CMR glc , but it does suggest that the rates of brain glucose transport and metabolism may be different in the hypothalamus than in the cortex.
In summary, we observed that glucose transport kinetics in the hypothalamus of healthy humans with experimentally induced HAAF were not different from those measured in the absence of HAAF. Our observations do not support the hypothesis that upregulation of glucose transport contributes to the development of HAAF in patients with diabetes and recurrent hypoglycemia, although future studies of patients with diabetes and impaired awareness of hypoglycemia will be necessary to determine if the existence of the diabetes state is required for this adaptation to hypoglycemia to occur.
